

BREAST CANCER FAMILY REGISTRY (BCFR) COHORT

APPLICATION TO COLLABORATE WITH THE BCFR

1. Applicant

Date of Submission	
Title of Application	
Key words	1. 2. 3. 4.
Lead Investigator (Name, Affiliation, Address, Phone number, email)	
Other Investigators (Name and Affiliation)	

2. Summary of Application

	Mark X	
Potential Collaborating BCFR Sites		Australian Site PI: John L. Hopper, Ph.D. (j.hopper@unimelb.edu.au)
		New York Site PI: Mary Beth Terry, Ph.D. (mt146@columbia.edu)
		Northern California Site PI: Esther M. John, Ph.D. (esther.john@cpic.org)
		Ontario Site PI: Irene Andrulis, Ph.D. (andrulis@lunenfeld.ca)
		Philadelphia Site PI: Mary Daly, M.D., Ph.D. (mary.daly@fccc.edu)
		Utah Site PI: Saundra S. Buys, M.D. (saundra.buys@hci.utah.edu)
Type of Study		Pilot Study
		Full Study
Study Design		Population-based case-control analysis (case probands and population controls)
		Family-based case-control analysis (affected subjects, unaffected relatives)
		Case-only analysis
		Prospective cohort analysis
		Other (<i>specify</i>):
Funding		Funding Pending
		Funding Obtained
		<i>Specify funding source and grant number:</i>
IRB/Ethics approval		IRB/ethics approval pending
		IRB/ethics approval obtained
		<i>Specify date of IRB/Ethics approval:</i>

3. Collaborations & Publications Agreement

I hereby agree to adhere to the requirements listed in the document “Requirements and Guidelines for Collaborations and Publications”.

4. Return of Data to the BCFR

I hereby agree to make the study results available to the scientific community by transferring them to the central database within 6 months after their publication.

5. Acknowledgment Agreement

I hereby agree to acknowledge the contributions of the Breast Cancer Family Registry in all publications resulting from the use of the data and/or biospecimens obtained as follows:

“This work was supported by grant UM1 CA164920 from the National Cancer Institute. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the Breast Cancer Family Registry (BCFR), nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government or the BCFR.”

**Applicant's
Printed Name**

**Applicant's
Signature**

Date

6. Description of Proposed Collaborative Study

Provide a brief description of the study design, not to exceed 4 pages of text. The application should include the following sections:

Abstract – not to exceed one half page

Specific Aims

Background and Significance – including hypotheses and a statement that the resources of the BCFR are essential to the study.

Preliminary Data – for proposals using BCFR biospecimens (e.g., DNA, plasma, tumor tissue, cell lines), provide data to demonstrate that applicant has the relevant expertise to conduct the assays performed.

Study Design and Methods – study design, study population, types of assays to be performed, markers to be measured, biospecimen requirements, data requirements, statistical analysis plan, and power calculations.

Timeline

7. Type of Data Requested

Mark x	
	Family History Data
	Baseline Epidemiology Data
	Baseline Dietary Data
	Follow-up Epidemiology Data
	Outcomes Data
	Pathology Data
	BRCA1 and BRCA2 data
	Other Data (specify)

8. Type of Biospecimens Requested

	Selection Criteria for Subjects	Amount requested
Example:		
DNA from Lymphocytes	Population-based probands diagnosed under the age of 35 yrs	50 ng
DNA from Lymphocytes		
DNA from Cell Lines		
DNA from Buccal Cells		
Cell Lines		
Plasma		
Tumor Tissue: archived slides		
Tumor Tissue: TMA		
Other (specify)		

Other requirements regarding biospecimens (specify):

Submit to Ms. Ly Ngo, BCFR Review Coordinator, at ly.ngo@cpic.org

- Completed Application
- Description of Proposed Collaborative Study (4 pages maximum)
- Biosketch of Applicant

Additional BCFR Contacts

BCFR Administrative Coordinating Center: Esther M. John, Ph.D.: esther.john@cpic.org

Web address: <http://www.bcfamilyregistry.org/>

OFFICE USE ONLY

Proposal Number	
Date Proposal Received	
Date Proposal Reviewed by SC	
Outcome of Review	
Approved	
Disapproved	
Collaborating BCFR Sites	
Australia	
New York	
Northern California	
Ontario	
Philadelphia	
Utah	
Assigned BCFR Liaison	